Eledon Pharmaceuticals (ELDN) News Today $4.29 -0.05 (-1.15%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.30 +0.00 (+0.12%) As of 02/21/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Leerink Partnrs Has Pessimistic View of ELDN Q4 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.32) per shFebruary 10, 2025 | marketbeat.comEledon Pharmaceuticals' Investigational Therapy Tegoprubart Successfully Used in Landmark Kidney Xenotransplant at Mass General Transplant CenterFebruary 9, 2025 | nasdaq.comEledon's tegoprubart used in second pig-to-human kidney transplantFebruary 7, 2025 | msn.comEledon announces tegoprubart use in transplant of pig kidney into humanFebruary 7, 2025 | markets.businessinsider.comEledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a HumanFebruary 7, 2025 | globenewswire.comFY2029 Earnings Estimate for ELDN Issued By Leerink PartnrsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the companyFebruary 7, 2025 | marketbeat.comEledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comEledon Pharmaceuticals initiated with a Buy at GuggenheimJanuary 28, 2025 | markets.businessinsider.comEledon initiated with a Buy at Guggenheim on tegoprubart opportunityJanuary 28, 2025 | markets.businessinsider.comEledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessJanuary 28, 2025 | seekingalpha.comEledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at GuggenheimGuggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $9.00 target price for the company.January 28, 2025 | marketbeat.comInspire Investing LLC Invests $802,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Inspire Investing LLC acquired a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 194,688 shares of the company's stock, valued at approximately $802,000.January 25, 2025 | marketbeat.comBrokers Set Expectations for ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Eledon Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnJanuary 22, 2025 | marketbeat.comEledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top AnalystJanuary 16, 2025 | markets.businessinsider.comEledon Pharmaceuticals highlights recent business milestones, 2025 outlookJanuary 13, 2025 | msn.comEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 OutlookJanuary 13, 2025 | globenewswire.comEledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 3.9% - Time to Sell?Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.9% - Time to Sell?January 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest UpdateEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 686,700 shares, a drop of 6.1% from the November 15th total of 731,500 shares. Based on an average trading volume of 432,200 shares, the days-to-cover ratio is currently 1.6 days.December 16, 2024 | marketbeat.comQ4 EPS Forecast for Eledon Pharmaceuticals Cut by AnalystEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now expects that theNovember 22, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Eledon Pharmaceuticals in a research note on Wednesday.November 20, 2024 | marketbeat.comResearch Analysts Set Expectations for ELDN FY2024 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings per share estimates for Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the compaNovember 18, 2024 | marketbeat.comEledon Pharmaceuticals: Strong Financials and Promising Clinical Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for ELDN Issued By Lifesci CapitalEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Lifesci Capital lifted their FY2024 EPS estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per sNovember 15, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutionsNovember 14, 2024 | finance.yahoo.comEledon Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comEledon Pharmaceuticals price target lowered to $20.50 from $28 at LadenburgNovember 14, 2024 | markets.businessinsider.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comEledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Make Eledon Pharmaceuticals a Compelling InvestmentOctober 30, 2024 | markets.businessinsider.comNoble Financial Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)October 30, 2024 | markets.businessinsider.comBuy Rating Justified for Eledon Pharmaceuticals Amid Promising Clinical Developments and Financial StabilityOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offeringOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial DataOctober 29, 2024 | marketwatch.comEledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartOctober 29, 2024 | seekingalpha.comEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsOctober 29, 2024 | globenewswire.comEledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineOctober 29, 2024 | globenewswire.comEledon Pharma (NASDAQ:ELDN) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comNantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Nantahala Capital Management LLC purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 600,000 shares of the company's stoOctober 1, 2024 | marketbeat.comEledon Pharmaceuticals’ Tegoprubart: A Strong Buy Based on Industry-Wide Validation and Promising Drug DataSeptember 24, 2024 | markets.businessinsider.comEledon Pharmaceuticals to Present at the Cantor Global Healthcare ConferenceSeptember 11, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Opthea Limited Sponsored ADR (OPT)September 9, 2024 | markets.businessinsider.comEledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant PatientsSeptember 4, 2024 | globenewswire.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Earn Q3 2024 Earnings of ($0.20) Per ShareEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2024 earnings estimates for Eledon Pharmaceuticals in a research report issued on Tuesday, August 20th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.2August 23, 2024 | marketbeat.comBuy Rating Justified by Eledon Pharmaceuticals’ Strategic Progress and Growth PotentialAugust 22, 2024 | markets.businessinsider.comVanguard Group Inc. Buys 273,703 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Vanguard Group Inc. raised its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 39.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 969,121 shares of the company's stock afteAugust 20, 2024 | marketbeat.com2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360%August 19, 2024 | msn.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 16.1% in JulyEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 108,100 shares, a decline of 16.1% from the July 15th total of 128,800 shares. Based on an average daily volume of 158,400 shares, the short-interest ratio is presently 0.7 days.August 16, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating ResultsAugust 15, 2024 | finanznachrichten.deEledon Expects to Restate Results, Delays Quarterly ReportAugust 14, 2024 | marketwatch.com Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELDN Media Mentions By Week ELDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼-0.050.60▲Average Medical News Sentiment ELDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼01▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRVI News Today ELVN News Today PAHC News Today ZYME News Today ABCL News Today REPL News Today COLL News Today RCKT News Today EOLS News Today PHVS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELDN Stock Alerts